AT13148 (AT-13148)是新型可口服的、ATP竞争性多AGC kinase抑制剂，具有强大的药效学和抗肿瘤活性。AT13148对Akt1/2/3、PKA、p70S6K和ROCKI/II的IC₅₀分别为38 nM/402 nM/50 nM、3 nM、8 nM和6 nM/4 nM，与其他AKT抑制剂作用机制不同，同时抑制多种AGC激酶可能会增加抗肿瘤活性并最大限度地减少临床耐药性。

参考文献

1.Yap TA, et al. AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. Clin Cancer Res. 2012 Jul 15;18(14):3912-23.

2.Xi Y, et al. AT13148, a first-in-class multi-AGC kinase inhibitor, potently inhibits gastric cancer cells both in vitro and in vivo. Biochem Biophys Res Commun. 2016 Sep 9;478(1):330-6.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。